PDCD1 and neoplasm: However, the clinical benefit of adding anti-CTLA-4 to anti-PD-1/PD-L1 therapy appears greatest in TMB-high tumors, which have increased tumor immunogenicity resulting from high expression of tumor neoantigens [32, 33].